Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial

Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial

Abstract We previously reported the results of a randomized phase II trial (NCT02904954) in patients with early-stage non-small cell lung cancer (NSCLC) who were treated with either two preoperative cycles of the anti-PD-L1 antibody durvalumab alone or combined with immunomodulatory doses of stereot...

Full description

Bibliographic Details
Main Authors: Nasser K. Altorki, Zachary H. Walsh, Johannes C. Melms, Jeffery L. Port, Benjamin E. Lee, Abu Nasar, Cathy Spinelli, Lindsay Caprio, Meri Rogava, Patricia Ho, Paul J. Christos, Ashish Saxena, Olivier Elemento, Bhavneet Bhinder, Casey Ager, Amit Dipak Amin, Nicholas J. Sanfilippo, Vivek Mittal, Alain C. Borczuk, Silvia C. Formenti, Benjamin Izar, Timothy E. McGraw
Format: Article
Language:English
Published: Nature Portfolio 2023-12-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-023-44195-x

Similar Items

Similar Items